Advertisement
Advertisement
U.S. Markets open in 7 hrs 10 mins
Advertisement
Advertisement
Advertisement
Advertisement

Mydecine Innovations Group Inc. (MYCOF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1450+0.0011 (+0.76%)
At close: 03:59PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1439
Open0.1480
BidN/A x N/A
AskN/A x N/A
Day's Range0.1392 - 0.1600
52 Week Range0.0100 - 2.2000
Volume637,554
Avg. Volume916,288
Market Cap34.609M
Beta (5Y Monthly)4.55
PE Ratio (TTM)N/A
EPS (TTM)-0.0900
Earnings DateNov 16, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
  • GlobeNewswire

    Mydecine Partners with Combat Stress to Treat Post-Traumatic Stress Disorder in Veterans

    Study further supports the expansion of clinical trials of MYCO-001 for the treatment of PTSD among the Veteran populationDENVER, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced a partnership with Combat Stress (Combat Stress) and the King's College London to utilize psilocybin a

  • GlobeNewswire

    Mydecine Signs LOI with The Newly Institute to Provide Psychedelic-Assisted Psychotherapy to Patients under Health Canada’s Special Access Program

    Under Mydecine’s recently announced Special Access Support and Supply Program, the Company will supply cGMP Psilocybin and MDMA to The Newly. The companies will partner to co-develop protocols, therapy manuals, and training needed to treat patients who need specific care.VANCOUVER, British Columbia, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the

  • GlobeNewswire

    Mydecine to Launch Special Access Support and Supply Program in Canada Expanding Access to Psychedelic-Assisted Psychotherapy For Patients

    With the addition of psilocybin and MDMA to Health Canada’s Special Access Program, Mydecine looks to offer a package of cGMP products and support services promoting responsible administration to patients and creating near-term revenue potentialVANCOUVER, British Columbia, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health

Advertisement
Advertisement